offer
all report title image
  • Published On : Aug 2022
  • Code : CMI203
  • Industry : Pharmaceutical
  • Pages : 163
  • Formats :

Pulmonary Hypertension (PH) is a rare disease that affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease usually worsens over time and can lead to death if left untreated. Due to the increase in the incidence of PAH (pulmonary arterial hypertension), the increase in the geriatric population, and the increasing government support for the development of orphan drugs, the market is expected to witness significant growth during the forecast period.

The global pulmonary arterial hypertension drug market is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to reach US$ 11,220.2 million by 2030, at a CAGR of 5.5% during the forecast period (2022–2030).

Figure 1. Global Pulmonary Arterial Hypertension Drug Market Share (%), By Region, 2022

Pulmonary Arterial Hypertension Drug  | Coherent Market Insights

An increasing number of heart failure causes pulmonary arterial hypertension (PH) cases, which is expected to increase significantly during the forecast period.

The pulmonary arterial hypertension drug market is expected to see significant growth during the forecast period as the number of heart failures continues to rise, which then leads to cases of pulmonary arterial hypertension (PAH). For instance, in 2019, Heart Failure Society of America reported that there are approximately 550,000 newly diagnosed heart failure cases in the U.S. each year, and nearly 1.4 million congestive heart failure (CHF) patients are under 60 years of age.

CMI table icon

Pulmonary Arterial Hypertension Drug Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 7,310.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.5% 2030 Value Projection: US$ 11,220.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others
  • By Route of Administration: Oral, Inhaled, Intravenous, Subcutaneous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.

Growth Drivers:
  • Increasing incidence of pulmonary arterial hypertension
  • Rising government support for the development of orphan drugs
  • Growing geriatric population
  • Product approvals by regulatory authorities
Restraints & Challenges:
  • Expiration of key molecule patents
  • Drug-related side effects
  • Lack of awareness among people in emerging countries
  • High costs of diagnosis and treatment

Figure 2. Global Pulmonary Arterial Hypertension Drug Market Share, By Drug Class, 2022

Pulmonary Arterial Hypertension Drug  | Coherent Market Insights

Increasing collaboration for the development of novel products is expected to drive growth of pulmonary arterial hypertension drug market over the forecast period.

Key players are focusing on collaborations and mergers to develop new products for the pulmonary arterial hypertension (PAH) market, which is expected to promote pulmonary arterial hypertension drug market growth during the forecast period. For example, in 2017, Bayer AG, a German multinational pharmaceutical and Life Sciences Company and Vectura Group Plc., a British pharmaceuticals business, expanded their collaboration to develop an improved version of the Breelib nebulizer, which improves the efficacy of iloprost aerosol in the treatment of pulmonary atrial hypertension.

Global Pulmonary Arterial Hypertension Drug Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 9, 2022, are approximately 583,038,110 confirmed cases with 6,416,023 deaths. The Coronavirus (COVID-19) outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.

Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, U.A.E., Egypt, and others are facing problems with regards to transportation of drugs from one place to another. However, the crisis due to coronavirus disease has given a boost to pharmaceutical companies to grow and develop an ambitious drug and vaccine projects with a sole aim to contain the viral outbreak. Such demanding R&D projects are in turn creating a wealth of opportunities for innovations in global pulmonary arterial hypertension drug market.

Global Pulmonary Arterial Hypertension Drug Market: Restraint

Factors such as expiration of key molecule patents, drug-related side effects such as gastric ulcers, hypotension, congestive heart failure, lack of awareness among people in emerging countries such as India Brazil, China and others, and high costs of diagnosis and treatment are expected to hamper the global pulmonary arterial hypertension drug market growth.

Key Players

Major players operating in the global pulmonary arterial hypertension drug market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.

Pulmonary arterial hypertension is a rare disease caused by many factors, such as congestive heart failure, liver disease, autoimmune diseases, such as lupus, scleroderma, rheumatoid arthritis, etc. The pulmonary artery is a blood vessel that carries blood from the right side of the heart to the lungs. This disease is considered a rare but life-threatening disease and will get worse over time. The arteries that are narrowed and blocked due to high blood pressure are called pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH). Thus, making it difficult for blood to pump through these arteries, subsequently causing the heart muscle to weaken.

Symptoms include shortness of breath, dizziness, and tightness in the chest. The exact cause of PAH is unknown, and although it can be treated, there is no known cure. Over time, the condition will get worse, but medications and oxygen therapy can help reduce symptoms and improve quality of life. PAH usually affects women between the ages of 30 and 60.

Market Dynamics

The increase in causes of pulmonary arterial hypertension (PAH) such as stroke is expected to drive the growth of global pulmonary arterial hypertension drug market over the forecast period. For instance, according to an article Heart Disease and Stroke Statistics 2019 published by the American College of Cardiology Foundation, a report from the American Heart Association, there are about 795,000 residents in the U.S. who have a new or recurrent stroke each year, in which 90.0% of stroke risk is due to modifiable risk factors and 74.0% is due to behavioral risk factors.

Key features of the study:

  • This report provides an in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021  as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market

Detailed Segmentation:

  • Global Pulmonary arterial hypertension Drug Market, By Drug Class:
    • Endothelin Receptor Antagonists (ERAs)
    • Phosphodiesterase-5 (PDE-5) Inhibitors
    • Soluble Guanylate Cyclase (sGC) Stimulators
    • Prostacyclin Analogue
    • Calcium Channel Blockers
    • Others
  • Global Pulmonary arterial hypertension Drug Market, By Route of Administration:
    • Oral
    • Inhaled
    • Intravenous
    • Subcutaneous
  • Global Pulmonary arterial hypertension Drug Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pulmonary arterial hypertension Drug Market, By Region:   
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • United Therapeutics Corporation.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • GlaxoSmithKline plc.
    • Novartis AG
    • AstraZeneca
    • Bayer AG
    • Merck KGaA
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Actelion Pharmaceuticals Ltd
    • Arena Pharmaceuticals
    • Daiichi Sankyo Company, Limited
    • Sandoz AG
    • Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Mylan N.V.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global pulmonary arterial hypertension drug market size is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to exhibit a CAGR of 5.5% between 2022 and 2030.
Increasing incidence of pulmonary arterial hypertension, rising government support for the development of orphan drugs, growing geriatric population, product approvals by regulatory authorities are the major factors driving the growth of the market.
Factors such as expiration of key molecule patents, drug-related side effects, lack of awareness among people in developing countries, high costs of diagnosis and treatment are the major factors restraining growth of the market.
Major players operating in the market includes United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.
North America is the most prominent region in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo